AVN-101

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
AVN-101

AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it is in phase II clinical trials for these indications.[2][3][4]

See also

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.

External links


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=AVN-101&oldid=713192748"